


Hikal Limited

Highest Ever Quarterly Operating Performance

- ✓ Sales of Rs. 351 Crore; Growth of 37%
- ✓ EBITDA of Rs. 67 Crore; Growth of 38%
- ✓ PBT of Rs. 34 Crore; Growth of 91%
- ✓ Interim Dividend increased to 35% from 30%

Mumbai, February 8th, 2018: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the quarter and nine months ended 31st December, 2017.

Highlights for Quarter Ended 31st December, 2017



Performance highlights for the quarter ended 31st December, 2017

- **Sales up 37% to Rs. 351 crore** as compared to Rs. 255 crore in the corresponding period of the previous year
- **EBITDA up 38% to Rs. 67 crore** as compared to Rs. 48 crore in the corresponding period of the previous year
- **PBT up 91% to Rs. 34 crore** as compared to Rs. 18 crore in the corresponding period of the previous year

Segmental Performance for the quarter ended 31st December, 2017

- **Crop Protection sales up 24% to Rs. 139 crore** as compared to Rs. 112 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 47% to Rs. 212 crore** as compared to Rs. 144 crore in the corresponding period of the previous year

Performance highlights for the nine months ended 31st December, 2017

- **Sales up 26% to Rs. 910 crore** as compared to Rs. 719 crore in the corresponding period of the previous year
- **EBITDA up 22% to Rs. 170 crore** as compared to Rs. 139 crore in the corresponding period of the previous year
- **PBT up 42% to Rs. 72 crore** as compared to Rs. 51 crore in the corresponding period of the previous year

Segmental Performance for the nine months ended 31st December, 2017

- **Crop Protection sales up 30% to Rs. 371 crore** as compared to Rs. 286 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 24% to Rs. 538 crore** as compared to Rs. 433 crore in the corresponding period of the previous year

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

“The capital investments and R&D efforts that we have made in the past few years, in both our crop protection and pharmaceutical divisions is yielding results. The operating performance shows a growth of 35% in revenue and 38% in EBITDA for the quarter. We expect this trend to continue as other new products get introduced from our pipeline, in the coming year.

Our Pharmaceutical Division showed a considerable growth of 47%. The Crop Protection business has grown significantly by 24% for the quarter.

As a company, we have maintained our EBITDA margins despite increases in raw material costs in the past few quarters. We are confident that the growth momentum will continue based on our expanding customer and product portfolio in both the Pharmaceutical and Crop Protection Division.

I am pleased to inform that Mr. Ranjit Shahani currently Vice Chairman & Managing Director of Novartis India Limited has joined our board as an additional director. He has a strong and diverse experience in the Pharmaceutical Industry spanning several decades and will be a great asset to the Company.”



About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi
anish_swadi@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Ms. Payal Dave
payal.dave@sgapl.net
+91 9819916314

www.sgapl.net